Chemotherapeutic drugs kill cancer cells mainly by direct cytotoxicity, but they might also induce a stronger host immune response by causing the tumor to produce costimulatory cell surface molecules like CD80. We previously reported that in myeloid leukemic cells, c-irradiation induced CD80 expression. In this study, we show that cytosine arabinoside (Ara-C), even at low doses, induced CD80 expression in vitro in mouse DA1-3b leukemic cells, by a mechanism that involved reactive oxygen species. In vivo experiments in the mouse DA1-3b/C3H whole-animal acute myeloid leukemia (AML) model showed that injection of Ara-C induced expression of CD80 and CD86, and decreased expression of B7-H1, indicating that chemotherapy can modify costimulatory molecule expression in vivo, in a way not necessarily observed in vitro. Mouse leukemic cells exposed in vivo to Ara-C were more susceptible to specific cytotoxic lymphocyte (CTL)-mediated killing. Ara-C also induced CD80 or CD86 expression in 14 of 21 primary cultured human AML samples. In humans being treated for AML, induction chemotherapy increased CD86 expression in the leukemic cells. These findings indicate possible synergistic strategies between CTL-based immunotherapy and chemotherapy for treatment. They also suggest an additional mechanism by which chemotherapy can eradicate AML blasts.
Introduction
Chemotherapeutic drugs kill cancer cells by direct cytotoxicity, but many reports have suggested that chemotherapy might also help the host to acquire an immune response against the tumor. In an animal model, and in some clinical studies, cyclophosphamide, melphalan, N,N 0 -bis(2-chloroethyl)-N-nitrosourea, vinblastine, and bleomycin enhanced the acquisition of T-cellmediated antitumor immunity. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] For example, in mouse lymphoma cells, DNA-alkylating agents alleviate silencing of class II transactivator gene. 12 Another possible mechanism could be the upregulation and/or neoexpression of costimulatory molecules or cytokines by tumor cells. For example, Mokyr and co-workers 13, 14 showed that in the MOPC-315 mouse plasmacytoma, melphalan, mitomycin, and g-irradiation enhanced CD80, INF-b, and TNF-a expression. They also demonstrated that upregulation of CD80 by chemotherapeutic drugs was mediated by enhanced NF-kB activity, and generation of reactive oxygen species. 15 We previously reported that in the WEHI-3b and DA1-3b murine leukemic cells, and in primary cultured human myeloid leukemic cells, g-irradiation induces expression of CD80. 16 Thus, anticancer treatments can modify in tumor cells the expression of molecules involved in immune response. Acute myeloid leukemia (AML) is treated by intensive induction chemotherapy followed by several cycles of consolidation therapy. The direct cytotoxic effect of chemotherapy induces most of the reduction of the leukemic mass, but an antileukemic immune response might also help to maintain patients in complete remission. Chemotherapy during minimal residual disease might modify the expression of costimulatory molecules or cytokines on the leukemic cells. To examine if chemotherapeutic drugs used in AML could modulate the immune response against leukemic cells, we first exposed the DA1-3b murine leukemic cell line to cytosine arabinoside (Ara-C) in vitro, and then in a whole-animal model, and analyzed expression of costimulatory molecules CD80, CD86, and B7-H1 (PD-L1) which has been recently reported as an inhibitor of antitumor T-cell immunity. 17, 18 We then tested the susceptibility of leukemic cells exposed to Ara-C to lysis by cytotoxic T lymphocytes (CTL). Finally, we measured the expression of costimulatory molecules induced by Ara-C in primary cultured leukemic cells from patients with AML.
Material and methods

Cells, tissue samples, and culture conditions
The mouse leukemic DA1-3b cell line was maintained in liquid culture in DMEM medium (Life Technologies, Gaithersburg, MD, USA) supplemented with 10% fetal calf serum (FCS), 100 IU penicillin, 100 mg/ml streptomycin, and 2 mM L-glutamine. 19 Fresh human leukemic cells were obtained, following informed consent, from the peripheral blood of 25 patients with AML who had greater than 90% circulating blast cells. AML cells were maintained in liquid culture in Iscove's medium (Life Technologies, Gaithersburg, MD, USA) supplemented with 10% FCS, 100 IU penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine, 20 ng/ml human recombinant stem cell factor (SCF: Tebu, Le Perray en Yvelines, France), 8 ng/ml interleukin 3 (IL-3; Tebu), and 20 ng/ml granulocyte-macrophage colony-stimulating factor (GM-CSF; Schering Plough, Levallois Perret, France).
In vitro exposure of cells to Ara-C and other factors Murine DA1-3b cells were incubated for at least 48 h with 0.1-4 mM Ara-C, and then studied by flow cytometry. As 4 mM Ara-C led to the best CD80 expression, this was used in all further experiments.
In some experiments, 25-100 mM N-acetyl-L-cysteine (NAC) was added 1 h before the addition of Ara-C to inhibit NF-kb as previously described. 20 Cells were exposed to heat shock and oxidative stress as previously described. 16 Briefly, for heat shock, the cells were exposed at 421C for 2 h and then returned to 371C for 18 h before flow cytometry analysis of CD80, CD86, and B7-H1 expression. For oxidative stress, H 2 O 2 was added to culture medium to give a final concentration of 1 mM, and cells were incubated for 18 h before analysis. In some experiments, 5-aza-2 0 -deoxycytidine added to culture medium to give a final concentration of 5 mM, and cells were cultured for 48 h before analysis. The g-irradiation treatment consisted of exposing cells to 25 Gy from a 137 Cs source. Cells were then washed and further cultured for 48 h before analysis.
Primary cultured human leukemic cells were cultured for 48 h after isolation, Ara-C was added, and cells were further cultured for another 48 h, before analysis.
Flow cytometry
Mouse cells were incubated with CD16/CD32 Fc blocking antibody (BD Pharmingen, San Diego, CA, USA) and then stained for CD80, CD86, and B7-H1 using mouse FITC-CD80, mouse PE-CD86 monoclonal antibody (BD Pharmingen), and mouse PE-B7-H1 monoclonal antibody (CliniSciences, Montrouge, France). Cells were analyzed on an EPICS XL3C flow cytometry system (Coulter). Dead cells were excluded from analysis by propidium iodide uptake.
Human AML cells were washed twice with phosphatebuffered saline (PBS), incubated with Fc-block reagent (Miltenyi Biotec, Bergisch Gladbach, Germany), stained with monoclonal antibodies against CD80, CD86 (BD Pharmingen, San Diego, CA, USA) and B7-H1 (CliniSciences) and then washed twice with PBS.
Whole-animal model of AML
Approximately 5 Â 10 6 DA1-3b cells were injected intraperitoneally into 8-week-old syngeneic C3H/Hej mice (IFFA CREDO, Lyon, France), 10 mice per group. After 2 weeks, animals developed symptoms of acute leukemia with massive spleen involvement, as previously reported. 21 Mice were then subcutaneously injected with 100 or 200 mg/kg/day Ara-C for 3 days. At 24 h after the last injection of Ara-C, mice were killed, spleens were removed, and DA1-3b cells were isolated for analysis by flow cytometry for CD80, CD86, and B7-H1 expression.
Cytotoxic lymphocyte assay
Generation of CTLs with specific activity against DA1-3b cells in the C3H/Hej mouse has been previously described. 19 Briefly, 15 mice were injected subcutaneously with 10 6 irradiated IL-12 transduced cells, and lymphocytes were isolated from spleen with the Miltenyi Biotec separation column using an anti-CD90 (Thy1.2) monoclonal antibody (Miltenyi Biotec). CD90 þ cells were cocultured with irradiated DA1-3b cells and 20 IU murine IL2/ml (Peprotech, Rocky Hill, NJ, USA) in 3 ml/ well in a six-well tissue culture plate. CTL activity was measured after 15 days using the CytoTox 96 nonradioactive cytotoxicity assay (Promega, Madison, WI, USA), with cultured CD8a þ cells isolated and purified with a selection kit (Miltenyi Biotec) as effectors, and DA1-3b cells as targets. Controls included cells isolated from DA1-3b-IL12 vaccinated mice as effectors, and cells from an EL4-BCR/ABL transfected cell line and the YAC-1 cell line as targets. Control experiments were performed with anti-H2-Kk, -I-Ak, -CD4, -CD8a (Pharmingen) blocking antibodies.
Real-time PCR and p65 NF-kB binding activity p65 NF-kB mRNA (Rel A) was evaluated using the following primers: 5 0 -GGA GGA GTC CGG AAC ACA ATG GCC ACT TGC C-3 0 , 5 0 -CTG CCG AGC TCA AGA TCT GCC GAG TAA AC-3 0 . Amplification was performed in SYBR Green PCR Master Mix (Applied Biosystems), according to the manufacturer's recommendations, with 18S as internal standard. All amplifications were carried out in the ABI/Prism 7700 Sequence Detector System (Applied Biosystems).
p65 NF-kB binding activity in DA1-3b cells nuclear and cytoplasmic extracts was determined by an ELISA-based assay using the TransAMt NF-kB p65 transcription factor assay kit (Active Motif, Carlsbad, CA, USA), according to the manufacturer's instructions.
Statistical analysis
Statistical analysis was performed using the Sigma Stat 3.0. software (SPSS Science). Induced costimulatory molecules by Ara-C in AML R Vereecque et al
Results
Induction of CD80 expression in murine DA1-3b leukemic cells DA1-3b leukemic cells exposed in vitro to increasing concentration of Ara-C showed maximal expression of CD80 at 4 mM, after which the cell viability dropped significantly (Figure 1a ). Increased CD80 expression was observed at Ara-C concentrations as low as 0.01 mM and maximal mean fluorescence intensity was obtained at 4 mM. In cells exposed to 4 mM Ara-C, CD80 expression increased rapidly and peaked at 72 h, after which it remained stable for 2 days (Figure 1b) . No modification of expression could be observed for CD86, which remained undetectable, and for B7-H1, which was expressed by 100% of cells (data not shown).
To determine whether upregulation of CD80 could be due to promoter demethylation, DA1-3b cells were cultured in 5 mM (Figure 2a) . As in our previous experiments with irradiated cells, g-irradiation, and H 2 O 2 but not heat shock increased CD80 expression (Figure 2a) . We also assessed the effect of actinomycin D and of cycloheximide, inhibitors of RNA synthesis and of protein synthesis respectively. As seen in Figure 2b , they decreased CD80 on the cell surface 48 h after Ara-C treatment, suggesting that upregulation of CD80 in vitro requires RNA synthesis and protein synthesis.
The findings that g-irradiation and H 2 O 2 treatment mimicked the effect of Ara-C on CD80 expression, coupled with reports by other investigators that chemotherapeutic drugs or g-irradiation can increase the level of intracellular reactive oxygen species, prompted us to determine whether the antioxidant NAC could block the effect of Ara-C on CD80 expression. As seen in Figure 3a , incubation with NAC 1 h before Ara-C treatment diminished the effect of Ara-C on CD80, indicating that reactive oxygen species are involved in CD80 expression. More recently, Mokyr et al demonstrated that NF-kB activity was also involved in upregulation of CD80 on tumor cells in response to chemotherapeutic drugs, and we previously reported that girradiation also enhanced p65 NF-kB expression in leukemic cells. 15, 20 As seen in Figure 3b , Ara-C treatment also increased p65 NF-kB mRNA in DA1-3b cells (Figure 3b ). The analysis of p65 NF-kB-binding activity using an ELISA-based array showed enhanced activity in nuclear extracts (P ¼ 0.03, Student's t-test) isolated from DA1-3b cells treated with Ara-C (Figure 3c ). Thus, induction of CD80 may involve both raised levels of intracellular reactive oxygen species, induction of p65 NF-kB expression and binding activity.
Expression of CD80, CD86, and B7-H1 after in vivo exposure of DA1-3b cells to Ara-C, and susceptibility to CTL-mediated lysis
In vivo administration of Ara-C to leukemic mice also changed the expression of costimulatory molecules in DA1-3b cells. Results were different from those obtained in vitro, as CD86 expression increased (Po10 À4 , Student's t-test) (Figure 4a and  b) , and in some mice, B7-H1 expression decreased slightly (P ¼ 0.019) (Figure 4c) .
We also tested the susceptibility of DA1-3b cells to lysis by purified CD8a þ CTL. DA1-3b cells exposed in vivo to Ara-C showed an increased percentage of cells lysed, by comparison with control cells (Figure 5a ). We also investigated in vitro how long the susceptibility of DA1-3b cells to lysis lasted, when Ara-C was removed from the culture medium. As seen in Figure 5b , the percentage of cells lysed peaked 7 days after discontinuation of Ara-C and cell washing. However, on day 14, the percentage of cells lysed returned to that of control cells.
Expression of costimulatory molecules on primary culture human AML cells exposed to Ara-C
To determine whether the upregulation of CD80 or CD86 observed in mice in vivo also occurs in human leukemic cells, we exposed primary cultured human AML cells to Ara-C. As seen in Figure 6a , exposure to Ara-C of 0.05 mM or more enhanced CD80 and CD86 expression (P ¼ 0.013 and P ¼ 0.002, respectively, paired t-test). These results were Induced costimulatory molecules by Ara-C in AML R Vereecque et al confirmed in a larger cohort of 21 patients (Figures 6 and 7) . After 48 h exposure to 4 mM Ara-C (Figure 7a and b) , nine and 14 samples showed increased CD80 (P ¼ 0.038, paired t-test) and CD86 (Po0.001) expression, respectively. This effect was more pronounced in M2, M4, M5 FAB subtypes and in AML postmyelodysplastic syndrome than in M0 and M1 AML ( Figure  6b and c). A total of 10 AML samples were also tested for B7-H1 expression but no variation was observed (data not shown).
To determine whether the changes observed in vitro could also result from leukemia treatment, CD80 and CD86 expressions were tested in three patients with AML, on day 0 and day 3 of Alpha 98-02 induction chemotherapy. The treatment was composed of daunorubicin 80 mg/m 2 /day d1-d3 and Ara-C 500 mg/m 2 /day d1-d3, mitoxantrone 12 mg/m 2 /day d8-d9, Ara-C 500 mg/m 2 /12 h d8-d9. AML cells were also cultured in vitro with Ara-C. In two samples, CD86 was slightly enhanced, both in vivo and in vitro (Figure 8 ).
Discussion
Ara-C can modify the expression of costimulatory molecules on the surfaces of mouse and human leukemic cells. Specifically, it enhanced CD80 expression in mouse DA1-3b cells, an effect previously reported after g-irradiation of leukemic cells, and after melphalan treatment of MOPC-315 plasmacytoma and P815 mastocytoma. 14, 15, 20 Enhanced CD80 expression required RNA synthesis and protein synthesis, and the inhibitory effect of the antioxidant NAC, coupled with increased p65 NF-kB transcription and binding activity, suggest that reactive oxygen species were involved. Effect of Ara-C on CD80 and CD86 expression on primary cultured human AML cells. (a) AML cells from seven patients were exposed to various concentrations of Ara-C for 48 h. Results are mean7s.d. (b) CD80 and (c) CD86 expression on primary cultured AML samples exposed to Ara-C, analyzed according to FAB subtype.
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We previously reported that g-irradiation and Ara-C could enhance transgene expression in murine and human leukemic cells transduced with various vectors used for gene therapy, and that reactive oxygen species and activation of NF-kB mediated this effect. 20 Donepudi et al 15 have demonstrated that when P815 tumor cells are exposed to melphalan, NF-kB binds to the promoter of the CD80 gene. Thus, chemotherapeutic agents that generate reactive oxygen species might modify the expression of several genes in leukemic cells. However, as the antioxidant NAC only partially counteracted the effect of Ara-C, another regulatory pathway could also be involved. This is supported by the observation that the CD80 and CD86 promoters have different responsive elements. [22] [23] [24] The effects of Ara-C in vivo were not exactly the same as in vitro. Besides the increase in CD80, a pronounced induction of CD86, and a slight decrease in B7-H1 were also observed. These findings indicate that Ara-C can synergize with microenvironment in vivo to modify the expression of costimulatory molecules. However, differences between Ara-C concentration in the plasma of treated mice with those obtained with in vitro continuous exposure to Ara-C might also account for the observed effects.
Several studies in animal models and in human cancer have shown that chemotherapy can enhance antitumor T-cell immunity. In mice bearing large plasmacytoma tumors, CD80 and CD86 expression contribute to the effectiveness of low-dose chemotherapy.
14, 25 Other groups described, in mouse AML and lymphoma models, synergistic effects between a leukemic cell vaccine (generated by gene transfer of IL-12 or injection of soluble B7-IgG), and chemotherapy. [26] [27] [28] We show here that mouse leukemic cells exposed in vivo to Ara-C were more susceptible to CTL-mediated cell killing, suggesting that the combined effects of cell vaccine and chemotherapy observed in other models could be partly due to direct effects on the tumor cells themselves. To validate in human cells some of the results observed in mouse cells, we analyzed CD80, CD86, and B7-H1 expression in primary cultured human AML cells. Exposure to doses of Ara-C as low as 0.05 mM led to a marked increase of CD86 and to a lesser increase of CD80, while B7-H1 remained unaffected. Most samples showed enhanced expression of either CD80 or CD86, but some subtypes of AML, especially FAB M0 and M1, showed no modification, or a decrease of expression. We also observed in two patients with AML an enhanced CD86 expression in leukemic cells obtained at day 3 of induction chemotherapy. These findings are slightly different from those observed previously with g-irradiation, as Ara-C induced CD86 rather than CD80, even at low dose. This suggests that chemotherapy and radiation might act in humans by different regulatory pathways. 16 Our data, combined with previous experiments in various mouse tumor models, suggest a possible combined therapeutic strategy, namely ex vivo expansion of antileukemic CTLs and reinjecting them into the patient after induction or consolidation therapy. Leukemic cells exposed to chemotherapeutic agents appear highly sensitive to CTL-mediated killing and perhaps are more immunogenic, because they express more costimulatory molecules. AML cells naturally secrete interferon-g and IL-12 and it seems possible, at least in some cases, to differentiate blast cells in vitro into dendritic cells able to stimulate Induced costimulatory molecules by Ara-C in AML R Vereecque et al autologous CTL expansion, with specific activity against AML cells. [29] [30] [31] [32] [33] [34] Expansion of specific CTL has also been reported using nonleukemic dendritic cells. 35 However, the optimal schedule to reinject these expanded CTL remained to be defined. It seems likely that immunotherapy would be more efficient against minimal residual disease, rather than against the tumor at initial diagnosis. Our study suggests that a synergistic effect might be obtained when CTL are reinjected after consolidation chemotherapy, because that is when residual leukemic cells are sensitized to CTL by Ara-C and perhaps by other drugs. We observed in vitro that this sensitization could last a week after the exposure to Ara-C, suggesting that reinjection of CTL into patients few days after chemotherapy could lead to a synergistic effect, and would avoid exposure of CTL to chemotherapeutic agents in vivo. Further investigations are required to confirm this hypothesis.
Another hypothesis is that chemotherapy enhances the immunogenicity of leukemic cells, and this contributes to the therapeutic effect in AML. Our data combined with results obtained by other groups using mouse models support this idea. The presence of circulating CTL in the peripheral blood, with specificity against leukemic antigen, in patients treated for CML and in healthy individuals, indicates that a natural antileukemic immune response might occur in vivo. 36, 37 Thus in AML, the specific antileukemic activity of CTL, acting in synergy with enhanced sensitivity of leukemic cells to immune-mediated cell killing induced by chemotherapy, might eradicate minimal residual disease. However, the functional activity of the CTL after recovery from chemotherapy remains to be determined.
Figure 8
Flow cytometry of CD86 expression in leukemic cells obtained from blood from two AML patients undergoing induction chemotherapy. Cells were collected and analyzed immediately before starting chemotherapy (day 0), and at day 3 of chemotherapy. Cells collected at day 0 were also cultured in vitro in presence of 4 mM Ara-C. Solid curve ¼ isotypic control, open curve ¼ CD86.
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